Pregnancy and Postpartum CGM in GDM
Purpose
Gestational diabetes (GDM) is one of the most common complications of pregnancy, and up to one third of women with GDM will have abnormal blood sugars after their pregnancy. To screen for abnormal blood sugars, standard of care is a 4-12 week postpartum oral glucose tolerance test (OGTT). However only 17-60% of women actually have this test performed. This study is to assess continuous glucose monitor data from the third trimester and up to 14 days postpartum to find predictors of postpartum OGTT results.
Condition
- Gestational Diabetes
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Diagnosis of gestational diabetes during current pregnancy - age 18 or older - prescribed Dexcom G7
Exclusion Criteria
- Pregestational diabetes - known skin adhesive allergy which inhibits ongoing use of CGM - chronic oral steroid use.
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| Participants with Gestational diabetes GDM | All participants who wear CGM and have their postpartum OGTT |
|
Recruiting Locations
New York, New York 10029
More Details
- Status
- Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
Detailed Description
Those with GDM in current pregnancy using a Dexcom Continuous Glucose Monitoring (CGM) are eligible for enrollment. Participants use their CGM as usual during pregnancy and wear one sensor postpartum. They have their standard of care OGTT performed at around 6 weeks. They then complete a remote questionnaire after OGTT.